*Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and Benicar HCT are registered trademarks of Daiichi Sankyo, Inc.; and Campral is a registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany.
Except for the historical information contained herein, this release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform act of 1995. These statements involve a number
of risks and uncertainties, including the difficulty of predicting FDA
approvals, the acceptance and demand for new pharmaceutical products, the
impact of competitive products and pricing, the timely development and
launch of new products, and the risk factors listed form time to time in
the Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on
Form 10-Q, and any subsequent SEC filings.
1. Jellinek MS, Snyder JB. Depression and suicide in children and
adolescents. Pediatr Rev 1998;19: 255-64. Birmaher B, Brent D, et al.
Practice parameters for the assessment and treatment of children and
adolescents with depressive disorders. J Am Acad Child Adolesc
Psychiatry. 1998;37(suppl 10):63S-82S.Note: securing primary source
2. Bhatia, MD S.K., Bhatia, MD S.C., Childhood and Adolescent Depression.
American Family Physician. 2007:Volume 75, Number 1
3. National Institute of Mental Health. Depression. Accessed November 1,
4. Mayo Clinic. Depression. Accessed November 1, 2007, at
|SOURCE Forest Laboratories, Inc.|
Copyright©2007 PR Newswire.
All rights reserved